0001193125-26-130401
SEC filingAura Biosciences deepened its operating losses in FY2025 amid continued investment in late-stage clinical development, with cash outflows rising and free cash flow deteriorating, reflecting the financial intensity of advancing bel-sar through pivotal trials.
Aura Biosciences reported an operating loss of $112.8 million for FY2025, a 17.3% increase from the prior year’s $96.1 million. This widening reflects intensified investment in the global Phase 3 CoMpass trial for bel-sar, the company’s lead candidate for early choroidal melanoma. The trial advancement represents a critical value inflection point but has significantly contributed to elevated research and development expenses. Management has consistently emphasized that R&D costs will rise for the foreseeable future as clinical development progresses.
Net cash used in operating activities increased to $84.7 million in FY2025, up from $79.8 million in FY2024. This trend aligns with the company’s disclosure that the net loss was compounded by increases in clinical and CRO prepaid expenses—direct outlays associated with executing late-stage trials. These prepayments are a structural feature of clinical outsourcing, where sponsors front-load payments to contract research organizations, creating near-term cash pressure even as services are delivered over time.
The company remains reliant on equity financing to sustain operations, having historically raised capital through preferred and common stock offerings. With no long-term debt or material non-cancelable commitments, Aura retains flexibility in vendor contracting, typically engaging on a cancelable purchase-order basis. However, management has disclosed substantial doubt about its ability to continue as a going concern beyond the next twelve months, signaling that additional funding will be required to advance bel-sar to regulatory approval.